| Complication | Evidence | PMID |
| Nephropathy | 1. we found high serum A-FABP4 but unchanged RBP4 concentrations and their associations with renal function and early diabetic nephropathy in type 2 DM. | 18305958 |
| Cardiovascular | 1. These findings suggest that FABP4 and FABP5 may represent mediators of and biomarkers for metabolic and cardiovascular disease in type 2 diabetes mellitus. | 20920650 |
| Atherosclerosis | 1. FABP4 up-regulation is responsible for the enhanced macrophage lipid accumulation by AGE, which may underlie the accelerated formation of foam cells and development of atherosclerotic cardiovascular diseases in diabetic patients. | 21336983 |
| Retinopathy | 1. FABP4 shows potential as a novel biomarker for DR prediction in Chinese patients with T2DM, and strict glycaemic control and more frequent retinal examination should be highlighted for T2DM patients with the highest quartile range of FABP4. | 29305311 |
| Dyslipidemia | 1. High FABP4 and low adiponectin levels are independent predictors of atherogenic dyslipidemia. | 29305311 |
| Insulin resistance and inflammation | 1. An integrated score combining FABP4 and FABP5 quartile data had even stronger associations with the metabolic syndrome, C-reactive protein, interleukin-6, and coronary artery calcium compared to either FABP alone. | 18421072 |
